Featured Research

from universities, journals, and other organizations

First Clinical Trial In Bay Area To Test Effect Of HIV Vaccine; SF Department Of Public Health And UCSF Recruiting Study Volunteers

Date:
March 9, 1999
Source:
University Of California San Francisco
Summary:
The first clinical trial in the Bay Area to test the effectiveness of an AIDS vaccine was launched this week through a joint project of the San Francisco Department of Public Health and the University of California San Francisco.

The first clinical trial in the Bay Area to test theeffectiveness of an AIDS vaccine was launched this weekthrough a joint project of the San Francisco Department ofPublic Health and the University of California SanFrancisco.

Related Articles


Known as a Phase III trial, the DPH/UCSF study will focus onthe ability of the test vaccine to protect the body againstHIV infection. It is part of a three-year, multi-siteclinical research effort that is the first in the U.S. tolook specifically at this aspect of a test vaccine.

The test vaccine is produced through genetic engineeringtechniques, so it is a synthetic product and does notcontain any live virus. It cannot cause HIV infection.

The test vaccine product, named AIDSVAX, was developed byVaxGen, a biotech company based in Brisbane, Calif. Theoverall trial is being carried out at more than 50 locationsthroughout North America with the goal of enrolling 5,000participants.

The DPH/UCSF team hopes to enroll 300 study volunteers. Study co-directors are Susan Buchbinder, MD, chief of theHIV Research Section at DPH, and James Kahn, MD, associateprofessor in the UCSF Positive Health Program at SanFrancisco General Hospital Medical Center.

The test vaccine is designed to train the immune system todevelop a defense mechanism against the outer covering ofHIV so the virus fails to spread throughout the body. It isnot known if this approach will be effective in protectingthe body against infection. Learning the answer is theoverall objective of the Phase III trial.

In order to take part, volunteers must be adults whocurrently are HIV-negative and at risk for HIV infectionthrough sexual exposure. All volunteers will receiveextensive counseling that will focus on reducing the chanceof becoming exposed to HIV.

The trial is a "double-blind" study with some participantsreceiving the test vaccine and some participants receiving aplacebo, an inactive substance used as a comparison. Neither the volunteers nor the research staff will knowwhich product is being administered. Participants receivethe test vaccine by injection.

The DPH/UCSF researchers emphasize that this trial involvesa test vaccine. They will not enroll anyone whose motive forparticipation is to use the vaccine as a reason to increaserisky exposures by counting on the vaccine to act asprotection against HIV.

"Participating in this trial is one way to make an importantcontribution to HIV vaccine research. But enrolling in thistrial is not a replacement for safe sex," Buchbinderstressed.

Organizing the trial involved careful consideration ofseveral ethical issues, added Kahn.

"The bottom line is that we want all the participants to beas safe as possible--whether they are in the vaccine groupor the placebo group--and for this reason, counseling is anintegral part of the trial," he said. "If participantsfollow some of the risk-reduction advice, it may influencethe outcome of our trial. That is fine with us. The goal isto prevent new infections. We still feel our results will bevalid in learning about the protective nature of a vaccine."

Earlier clinical studies of this vaccine evaluated itsoverall safety, including how it affected the immune systemand whether it caused any adverse reactions in researchvolunteers. Results of these studies, the Phase I and PhaseII trials, showed the vaccine to be safe in humans so far,and ready for evaluation at the next level.

The test vaccine contains two different synthetic versionsof gp120, a protein found on the outer coating of HIV. Thevaccine is designed to stimulate the body to produce whiteblood cells that specifically recognize the gp120 proteinand then produce antibodies to gp120. Vaccine researchershope that these antibodies will be able to recognize andbind to the gp120 protein on the surface of real HIV when itinfects the body, thereby preventing the virus from invadingthe body's immune system and setting up the mechanism ofcontinued HIV infection.

Study participants will undergo a series of seven vaccineinjections over a 30-month period. Blood samples will betaken and other tests conducted at regular intervals. Volunteers can enroll either through DPH or UCSF. Interested persons should call 415/514-4822 for completeinformation.

"It will take a sustained and probably lengthy effort todevelop a vaccine that stops HIV in San Francisco and aroundthe world," said Mitch Katz, MD, director of DPH. "Thistrial is a new and important step in fulfilling thatcommitment."

Thomas Coates, PhD, director of the UCSF AIDS ResearchInstitute, said, "This DPH/UCSF study represents the best inclinical research: using our local research strengthscollaboratively and taking new steps in the path towards apreventive AIDS vaccine."

"We will greatly benefit from the expertise these tworesearch groups bring to this important clinical trial,"said Don Francis, MD, DSc, president of VaxGen. "As a BayArea company, we are pleased to be working with the peopleof San Francisco to test this vaccine."

Both the DPH HIV Research Section and UCSF have been activein HIV vaccine research over the past 7 years.

DPH has a long history of working with people at risk forHIV infection since the 1970s, when it conducted studies ofhepatitis B in San Francisco. This research provided thefoundation for some of the earliest studies of the AIDSepidemic.

A UCSF team at San Francisco General established one of thenation's first HIV/AIDS units 15 years ago. It hasdeveloped into a comprehensive service with extensiveprograms in clinical care and research. Some of the newestprograms focus on people who are at high risk for HIVinfection, such as the Options project and Post-ExposurePrevention project.

In addition to the North American trial, VaxGen plans toenroll a group of 2500 men and women in Bangkok to test theeffectiveness of a version of the vaccine tailored for HIVstrains common in Thailand.


Story Source:

The above story is based on materials provided by University Of California San Francisco. Note: Materials may be edited for content and length.


Cite This Page:

University Of California San Francisco. "First Clinical Trial In Bay Area To Test Effect Of HIV Vaccine; SF Department Of Public Health And UCSF Recruiting Study Volunteers." ScienceDaily. ScienceDaily, 9 March 1999. <www.sciencedaily.com/releases/1999/03/990309063042.htm>.
University Of California San Francisco. (1999, March 9). First Clinical Trial In Bay Area To Test Effect Of HIV Vaccine; SF Department Of Public Health And UCSF Recruiting Study Volunteers. ScienceDaily. Retrieved December 21, 2014 from www.sciencedaily.com/releases/1999/03/990309063042.htm
University Of California San Francisco. "First Clinical Trial In Bay Area To Test Effect Of HIV Vaccine; SF Department Of Public Health And UCSF Recruiting Study Volunteers." ScienceDaily. www.sciencedaily.com/releases/1999/03/990309063042.htm (accessed December 21, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Sunday, December 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

The Best Tips to Curb Holiday Carbs

The Best Tips to Curb Holiday Carbs

Buzz60 (Dec. 19, 2014) It's hard to resist those delicious but fattening carbs we all crave during the winter months, but there are some ways to stay satisfied without consuming the extra calories. Vanessa Freeman (@VanessaFreeTV) has the details. Video provided by Buzz60
Powered by NewsLook.com
Sierra Leone Bikers Spread the Message to Fight Ebola

Sierra Leone Bikers Spread the Message to Fight Ebola

AFP (Dec. 19, 2014) More than 100 motorcyclists hit the road to spread awareness messages about Ebola. Nearly 7,000 people have now died from the virus, almost all of them in west Africa, according to the World Health Organization. Video provided by AFP
Powered by NewsLook.com
Researchers Test Colombian Village With High Alzheimer's Rates

Researchers Test Colombian Village With High Alzheimer's Rates

AFP (Dec. 19, 2014) In Yarumal, a village in N. Colombia, Alzheimer's has ravaged a disproportionately large number of families. A genetic "curse" that may pave the way for research on how to treat the disease that claims a new victim every four seconds. Duration: 02:42 Video provided by AFP
Powered by NewsLook.com
The Best Protein-Filled Foods to Energize You for the New Year

The Best Protein-Filled Foods to Energize You for the New Year

Buzz60 (Dec. 19, 2014) The new year is coming and nothing will energize you more for 2015 than protein-filled foods. Fitness and nutrition expert John Basedow (@JohnBasedow) gives his favorite high protein foods that will help you build muscle, lose fat and have endless energy. Video provided by Buzz60
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins